VTVT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
vTv Therapeutics Inc (VTVT) is not a strong buy at the moment for a beginner investor with a long-term horizon. The lack of positive financial performance, absence of significant trading signals, and neutral technical indicators suggest that waiting for more clarity on the company's clinical trial progress or financial improvement would be prudent.
The MACD is negatively expanding, RSI is neutral at 39.745, and moving averages are converging, indicating no clear trend. The stock is trading near its support level (S1: 35.674), but there is no strong technical signal for a buy.
The FDA's focus on Type 1 Diabetes as a therapeutic priority is also a positive catalyst.
Net income remains negative, and there is no recent news to suggest immediate catalysts for growth. Technical indicators are neutral to bearish, and there is no significant trading activity from insiders or hedge funds.
In Q4 2025, revenue dropped by 100% YoY to $0, gross margin also dropped to 0%, and net income improved slightly but remained negative at -$7.14M. EPS increased marginally to -0.57, up 3.64% YoY.
Analysts are bullish on the stock, with multiple Buy ratings and price targets ranging from $44 to $58. They highlight the potential of cadisegliatin as a first-in-class treatment for Type 1 Diabetes and its strong Phase 2 profile. However, the stock's current price of $36.51 is significantly below these targets, suggesting potential upside if the drug progresses successfully.
